1. Dujardin J-C, Decuypere S. Epidemiology of leishmaniasis in the time of drug resistance. In: Ponte-Sucre A, Padron-Nieves M, Diaz E, editors. Drug resistance in Leishmania parasites. Consequences, molecular mechanism and possible treatments. Wienen: Springer; 2013. p. 65–83.
2. Alvar J, Vélez ID, Bern C, Herrero M, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2002;7:e35671.
3. SEARO/WHO. Health Ministers commit to eliminating kalar azar [media advisory]. New Delhi: WHO Regional Office for South-East Asia; 2014. http://www.searo.who.int/mediacentre/releases/2014/pr1581/en/
4. WHO-TDR. Sustainable visceral leishmaniasis elimination requires research on infection reservoirs. TDR news item; 2016. http://www.who.int/tdr/news/2016/visceral-leishmaniasis-research/en/
5. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739–46.